SCHEMBL4413373

SCHEMBL4413373

N#Cc1c(Cl)nc(NCCO)nc1NC1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.40
CCNA2 P20248 2/20 0.40
CCNA1 P78396 2/20 0.40
EGFR P00533 1/20 0.40
ACHE P22303 3/20 0.39
AXL P30530 1/20 0.39
TYRO3 Q06418 1/20 0.39
MERTK Q12866 1/20 0.39
ADORA1 P30542 3/20 0.38
KDM4E B2RXH2 4/20 0.36
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CSNK2A1 P68400 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CDK1 P06493 1/20 0.34
SLC29A1 Q99808 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4413397 0.90 KDM4E (0.41) CDK2CCNA2CCNA1EGFRACHE
SCHEMBL4420256 0.84 CCNA2 (0.52) CDK2CCNA2CCNA1EGFRADORA1
SCHEMBL4417101 0.83 CCNA2 (0.42) CDK2CCNA2CCNA1EGFRACHE
SCHEMBL4416389 0.83 ACHE (0.43) ACHEADORA1KDM4ECSNK2A1ALDH1A1
SCHEMBL4416386 0.81 CCNA2 (0.47) CDK2CCNA2CCNA1EGFRADORA1
SCHEMBL4413356 0.81 CCNA2 (0.42) CDK2CCNA2CCNA1EGFRACHE
SCHEMBL11174566 0.76 HTT (0.41) CDK2ACHEKDM4EHTTTDP1
SCHEMBL11169614 0.75 PDE4A (0.44) ACHEADORA1KDM4EHTTCSNK2A1
SCHEMBL11163528 0.74 MEN1 (0.44) CDK2ACHEAXLTYRO3MERTK
SCHEMBL11175450 0.73 ACHE (0.38) ACHEADORA1KDM4EHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397351-B1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS HOFFMANN LA ROCHE (CH) 2009-11-11 EP disclosed
CN-1245391-C Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors HOFFMANN LA ROCHE (CH) 2006-03-15 CN disclosed
CN-1512988-A Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors - 2004-07-14 CN disclosed
EP-1397351-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2004-03-17 EP disclosed
US-6673795-B2 SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. 2004-01-06 US disclosed
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-03-27 US disclosed
WO-2002098864-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives P2RX5, IL5, P2RX2 CDK2 326/4885CCNA2 939/4885CCNA1 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.